From January 1, 2024 to March 31, 2024, the company has repurchased 11,804,907 shares, representing 1.45% for CNY 222.56 million. With this, the company has completed the repurchase of 17,763,061 shares, representing 2.2% for CNY 345.45 million under the buyback announced on July 17, 2023.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
27.58 CNY | -1.22% | -1.68% | +24.07% |
24/05 | Jafron Biomedical Co.,Ltd. Announces Final Dividend on A Shares for 2023, Payable on 31 May 2024 | CI |
26/04 | Jafron Biomedical Co.,Ltd. Proposes Final Dividend for the Year 2023 | CI |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+24.07% | 2.95B | |
-7.16% | 178B | |
-1.23% | 107B | |
-4.86% | 67.04B | |
-4.28% | 47.24B | |
+10.32% | 44.62B | |
+8.14% | 42.5B | |
+15.76% | 29.99B | |
+15.53% | 25.22B | |
-5.88% | 24.14B |
- Stock Market
- Equities
- 300529 Stock
- News Jafron Biomedical Co.,Ltd.
- Tranche Update on Jafron Biomedical Co.,Ltd.'s Equity Buyback Plan announced on July 17, 2023.